Table of Contents

September 3, 2013

Abstract CDC and NIDA Tout PrEP for HIV‐Negative Injecting Drug Users Monitor Vendor Protocols when Signing up for Drug Testing AAP OKs Breastfeeding on Methadone but Not Buprenorphine ONDCP and SAMHSA Release Opioid Toolkit, Promote Naloxone SAMHSA Releases Draft Outcome Measures, Gives 9/17 Deadline for Feedback DOJ to Allow Marijuana Ballot Initiatives to Go Forward […]

Read the full article →

Treatment Retention among Patients Randomized to Buprenorphine/Naloxone Compared to Methadone in A Multi‐site Trial

August 22, 2013

ConclusionsProvision of methadone appears to be associated with better retention in treatment for opioid dependence than buprenorphine, as does use of provision of higher doses of both medications. Provision of buprenorphine is associated with lower continued use of illicit opioids. (Source: Addiction) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm […]

Read the full article →

Buprenorphine Implants for Treatment of Opioid Dependence: Randomized Comparison to Placebo and Sublingual Buprenorphine/Naloxone

August 13, 2013

ConclusionsCompared with placebo, buprenorphine implants result in significantly less frequent opioid use, and are non‐inferior to sublingual buprenorphine/naloxone tablets. (Source: Addiction) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence

August 2, 2013

Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence. (Source: Drug Development Technology) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) – new on RxList

July 23, 2013

(Source: RxList – New and Updated Drug Monographs) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Buprenorphine therapy: an increasing challenge in oral and maxillofacial surgery

July 14, 2013

Suboxone is a 4:1 mixture of buprenorphine and naloxone and Subutex is buprenorphine alone. The high affinity μ-receptor binding of buprenorphine (Suboxone and Subutex) renders other opioids ineffective. Inadequate procedural sedation, inadequate analgesia, and significant drug interactions complicate the treatment of patients taking Suboxone or Subutex. Careful planning and an understanding of buprenorphine pharmacology can […]

Read the full article →

FDA OKs New Formula for Addiction Drug

July 10, 2013

(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Buprenorphine/Naloxone Therapy for Opioid Refractory Neuropathic Pain Following Traumatic Amputation: A Case Series

July 6, 2013

(Source: Military Medicine) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Orexo starts patient dosing in Phase III study of opioid dependence drug

June 22, 2013

Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

A randomised controlled trial of sublingual buprenorphine–naloxone film versus tablets in the management of opioid dependence

June 6, 2013

Conclusions: The study demonstrated dose equivalence and comparable clinical outcomes between the buprenorphine–naloxone film and tablet preparations, whilst showing improved dispensing times and patient ratings of satisfaction with the film. (Source: Drug and Alcohol Dependence)

Read the full article →

← Previous Entries

Next Entries →